ESR1 and breast carcinoma: To date, treatment planning for breast cancer patients has been based on a histologic analysis of the primary tumor and the expression of molecular markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).